Cholangiocarcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Phase 3b Study of Ivosidenib for Patients With Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: Ivosidenib Oral Tablet Sponsor:   Servier Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2023 Category: Research Source Type: clinical trials

Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String
Condition:   Perihilar Cholangiocarcinoma Intervention:   Device: Intrahepatic biliary stent with retrieval string Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Head and Neck Cancer;   Non Small Cell Lung Cancer Interventions:   Biological: WM-A1-3389;   Biological: Pembrolizumab Sponsors:   Wellmarker Bio;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Head and Neck Cancer;   Non Small Cell Lung Cancer Interventions:   Biological: WM-A1-3389;   Biological: Pembrolizumab Sponsors:   Wellmarker Bio;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Head and Neck Cancer;   Non Small Cell Lung Cancer Interventions:   Biological: WM-A1-3389;   Biological: Pembrolizumab Sponsors:   Wellmarker Bio;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Head and Neck Cancer;   Non Small Cell Lung Cancer Interventions:   Biological: WM-A1-3389;   Biological: Pembrolizumab Sponsors:   Wellmarker Bio;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Head and Neck Cancer;   Non Small Cell Lung Cancer Interventions:   Biological: WM-A1-3389;   Biological: Pembrolizumab Sponsors:   Wellmarker Bio;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Cholangiocarcinoma;   Head and Neck Cancer;   Non Small Cell Lung Cancer Interventions:   Biological: WM-A1-3389;   Biological: Pembrolizumab Sponsors:   Wellmarker Bio;   Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition:   Cholangiocarcinoma Intervention:   Drug: GNS561 + Trametinib Sponsor:   Genfit Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2023 Category: Research Source Type: clinical trials